ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
104,501.16
-0.33%
S&P 500
6,101.24
-0.29%
Dow Jones
44,424.25
-0.32%
US Dollar vs Yen
156.023
0.00%
Brent Oil
77.625
0.00%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Sutro Biopharma Inc (STRO)

  7. Sutro Biopharma Inc (STRO) ニュース

STRO

Sutro Biopharma (STRO)

Sutro Biopharma Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:STRO
日付受信時刻ニュースソース見出しコード企業名
2025/01/0806 : 05GlobeNewswire Inc.Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference NASDAQ:STROSutro Biopharma Inc
2025/01/0723 : 00GlobeNewswire Inc.Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scaleNASDAQ:STROSutro Biopharma Inc
2024/12/1022 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
2024/12/1022 : 00GlobeNewswire Inc.Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian CancerNASDAQ:STROSutro Biopharma Inc
2024/12/0406 : 09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
2024/11/1509 : 54Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
2024/11/1406 : 34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
2024/11/1406 : 30Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
2024/11/1406 : 30GlobeNewswire Inc.Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:STROSutro Biopharma Inc
2024/11/1223 : 34Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
2024/11/0506 : 05GlobeNewswire Inc.Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceNASDAQ:STROSutro Biopharma Inc
2024/11/0121 : 00GlobeNewswire Inc.Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLNASDAQ:STROSutro Biopharma Inc
2024/10/1105 : 05GlobeNewswire Inc.Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research ForumNASDAQ:STROSutro Biopharma Inc
2024/09/2105 : 09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
2024/09/2105 : 01GlobeNewswire Inc.Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:STROSutro Biopharma Inc
2024/09/1416 : 00GlobeNewswire Inc.Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024NASDAQ:STROSutro Biopharma Inc
2024/09/1121 : 00GlobeNewswire Inc.Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024NASDAQ:STROSutro Biopharma Inc
2024/08/2221 : 00GlobeNewswire Inc.Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung CancerNASDAQ:STROSutro Biopharma Inc
2024/08/1405 : 31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
2024/08/1405 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
2024/08/1405 : 30GlobeNewswire Inc.Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
2024/08/1405 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
2024/08/1305 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
2024/08/1305 : 38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
2024/08/1305 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
2024/07/1105 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
2024/07/1105 : 10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
2024/07/0921 : 00GlobeNewswire Inc.Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development OfficerNASDAQ:STROSutro Biopharma Inc
2024/06/1105 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
2024/06/1105 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:STRO

最近閲覧した銘柄

CCOM
US100
US Tech 100
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
AMEX
SPY
SPDR S&P 500
NASDAQ
AAPL
Apple
NASDAQ
NVDA
NVIDIA
PM
XAUUSD
Gold vs US Dollar
USOTC
RHHBY
Roche (QX)
NYSE
MCD
McDonalds
NASDAQ
AMZN
Amazon.com
USOTC
ADDYY
Adidas (QX)
USOTC
BASFY
BASF (QX)
USOTC
BNPQY
BNP Paribas (QX)
NYSE
DIS
Walt Disney
COIN
AVAXUSD
Avalanche
COIN
ADAUSD
Cardano
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有